MedPath

Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Phase 3
Conditions
Head and Neck Cancer
Registration Number
NCT00002659
Lead Sponsor
Matrix Pharmaceutical
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer.

PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer.

Detailed Description

OBJECTIVES: I. Compare the effect of intratumoral injection of a cisplatin/epinephrine gel (CDDP-e TI) to placebo gel for local control of recurrent or refractory squamous cell carcinoma of the head and neck. II. Assess achievement of a preselected (by the investigator) treatment goal for the most troublesome tumor in patients with recurrent or refractory squamous cell carcinoma of the head and neck following up to 6 weekly intratumoral treatments with CDDP-e TI vs. placebo gel. III. Compare the effect of CDDP-e TI to placebo gel on total local tumor volume per patient. IV. Evaluate the time to response and time to progression for the most troublesome tumor after local treatment with CDDP-e TI vs. placebo gel. V. Assess the improvement in or stabilization of quality of life in these patients as measured by the FACT-H\&N questionnaire. VI. Compare the histopathology of injected lesions that respond to local treatment.

OUTLINE: Randomized, double-blind study. Randomization weighted 2:1 in favor of Arm I. Arm I: Intratumoral Chemotherapy. Cisplatin (NSC-119875) and Epinephrine in a bovine collagen gel, MP 5010, CDDP-e TI. Arm II: Control. NS in a bovine collagen gel, PLCB.

PROJECTED ACCRUAL: Up to 120 evaluable patients will be studied to provide 80 evaluable patients on Arm I and 40 evaluable patients on Arm II.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (28)

Ville Marie Oncology Center

πŸ‡¨πŸ‡¦

Montreal, Quebec, Canada

Palmetto Richland Memorial Hospital

πŸ‡ΊπŸ‡Έ

Columbia, South Carolina, United States

Creighton University Cancer Center

πŸ‡ΊπŸ‡Έ

Omaha, Nebraska, United States

UCSF Cancer Center and Cancer Research Institute

πŸ‡ΊπŸ‡Έ

San Francisco, California, United States

Sylvester Cancer Center, University of Miami

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Oregon Cancer Center at Oregon Health Sciences University

πŸ‡ΊπŸ‡Έ

Portland, Oregon, United States

Department of Otolaryngology

πŸ‡ΊπŸ‡Έ

Milwaukee, Wisconsin, United States

Comprehensive Cancer Center at JFK Medical Center

πŸ‡ΊπŸ‡Έ

Atlantis, Florida, United States

Veterans Affairs Medical Center - Tucson

πŸ‡ΊπŸ‡Έ

Tucson, Arizona, United States

Evanston Northwestern Health Care

πŸ‡ΊπŸ‡Έ

Evanston, Illinois, United States

Arizona Cancer Center

πŸ‡ΊπŸ‡Έ

Tucson, Arizona, United States

Louisiana State University Hospital - Shreveport

πŸ‡ΊπŸ‡Έ

Shreveport, Louisiana, United States

Jonsson Comprehensive Cancer Center, UCLA

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Veterans Affairs Medical Center - Palo Alto

πŸ‡ΊπŸ‡Έ

Palo Alto, California, United States

Veterans Affairs Medical Center - Baltimore

πŸ‡ΊπŸ‡Έ

Baltimore, Maryland, United States

Methodist Cancer Center - Omaha

πŸ‡ΊπŸ‡Έ

Omaha, Nebraska, United States

University of Texas Southwestern Medical School

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

Thompson Cancer Survival Center

πŸ‡ΊπŸ‡Έ

Knoxville, Tennessee, United States

University of New Mexico Cancer Research & Treatment Center

πŸ‡ΊπŸ‡Έ

Albuquerque, New Mexico, United States

Capitol Comprehensive Cancer Care Clinic

πŸ‡ΊπŸ‡Έ

Jefferson City, Missouri, United States

Boston Cancer Group

πŸ‡ΊπŸ‡Έ

Memphis, Tennessee, United States

Montreal General Hospital

πŸ‡¨πŸ‡¦

Montreal, Quebec, Canada

Stanford University Medical Center

πŸ‡ΊπŸ‡Έ

Stanford, California, United States

University of Kentucky College of Medicine

πŸ‡ΊπŸ‡Έ

Lexington, Kentucky, United States

Washington University School of Medicine

πŸ‡ΊπŸ‡Έ

Saint Louis, Missouri, United States

Louisiana State University Medical Center - New Orleans

πŸ‡ΊπŸ‡Έ

New Orleans, Louisiana, United States

Southwest Regional Cancer Center

πŸ‡ΊπŸ‡Έ

Austin, Texas, United States

University of Kansas Medical Center

πŸ‡ΊπŸ‡Έ

Kansas City, Kansas, United States

Β© Copyright 2025. All Rights Reserved by MedPath